Drug intelligence / Profile preview

GSP15004

Development stage: Unknown
Lead developer: Green Sky Labs
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

GSP15004 is a pharmaceutical-grade drug candidate developed by Green Sky Labs for the treatment of neuropathic pain. Green Sky Labs is a biotechnology company specializing in the extraction, isolation, and formulation of active phytocannabinoids. While the exact chemical composition and molecular targets of GSP15004 are not publicly disclosed, the candidate is designed to target pain pathways, likely through modulation of the endocannabinoid system (such as CB1 and CB2 receptors). According to the developer's pipeline, GSP15004 has progressed to Phase 3 clinical development.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on GSP15004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSP15004.

Explore the full profile